Ornim Medical is an Israeli bio-medical high-technology company specializing in clinical research, development, and distribution of the highest quality medical devices for non-invasive patient monitoring specializing in the field of tissue and cerebral blood flow. Its two products, the CerOx™ and the c-FLOW™, are bedside patient monitors based on the patented UTLight™ technology designed to provide physicians with unique monitoring solutions that are imperative to individualized and personalized patient care.
Both products enable precise, real time, continuous and non-invasive measurements of cerebral blood flow alerting physicians to variations in blood flow to the brain, thus enabling informed intervention for better clinical results and patient care. Ornim’s CerOx™ monitor is the only device in the market today enabling simultaneous, non-invasive measurement of both blood flow and oxygen saturation; while the c-FLOW™ is a pared down version used to measure the CBF only.
The use of either of these products (depending on the clinical setting) is key to understand perfusion while helping to direct treatment and lower the cost of patient care. Ornim’s unique technology, protected by 13 worldwide granted and 15 worldwide pending patents, overcome limitations of Near Infrared Spectroscopy (NIRS) and ultrasound Doppler. The patented UTLight™ technology employs the combination of light and ultrasound to provide a non-invasive measure of regional blood oxygen saturation and blood flow.
UTLight™ technology is unique among all other commercially available NIRS technologies, since it also analyzes the light speckle signal and does not rely solely on the intensity of light reaching the detector. Ornim Medical has developed a product range that was born out of a need – a need to measure blood flow directly.
In other words, the products have the capabilities of direct measurement of flow (not surrogate like tissue oximetry); they are intuitive and comprehensive; actionable; the management of blood pressure (BP) according to CBF is intuitive; the measurement is robust and finally they are when adding the BP signal, the Autoregulation function of the organ can be assessed directly.
Latest funding size
Time since last funding
|over 1 year|
|Agate Medical Investments, GE Ventures, LongTec China Ventures, Fosun Group, OrbiMed|